抗乙肝病毒表面抗原嵌合抗体基因在昆虫细胞中的表达

应用杆状病毒表达系统在昆虫细胞中表达了抗乙肝病毒表面抗原（ＨＢｓＡｇ）人－鼠嵌合抗体重,轻链基因,鼠源单克隆抗体ＯＨ３重,轻链可变区（ＶＨ,ＶＬ）ｃＤＮＡ分别与人免疫球蛋白恒区γ３,ｋ,ｃＤＮＡ拼接成人－鼠嵌合抗体基因,含嵌合抗体的转移载体与线性化病毒ＤＮＡ共转染Ｓｆ９细胞,并通过点杂交ＰＣＲ扩增和Ｓｏｕｔｈｅｒｎｂｌｏｔ分析获得重组病毒。Ｗｅｓｔｅｒｎｂｌｏｔ和竞争ＥＬＩＳＡ表明以重组病毒感染的     

家蚕细胞和虫体产生抗人小细胞肺癌抗体

用重组昆虫病毒表达系统,在家蚕细胞和虫体表达了抗人小细胞肺癌人-鼠嵌合抗体。重组病毒rNPVL2,rNPVH17及双重组病毒rNPVLH19感染的家蚕细胞和虫体血淋巴中都检测到抗体分子的表达。双重组病毒的双基因共表达部分产物可装配。ELISA分析表明抗体重轻链基因共表达产物具有比单基因表达产物高得多的与小细胞肺癌细胞免疫结合功能。     

乙肝病毒表面抗原抗体可变区基因的克隆及人－鼠嵌合抗体重链基因的表达

本文采用反转录－聚合酶链反应（ＲＴ－ＰＣＲ）技术,从鼠抗乙肝病毒表面抗原（ＨＢｓＡｇ）单克隆细胞中克隆到了该抗体重、轻链可变区（Ⅴ区）基因,并分别将其与人的恒定区基因Ｃγ３,Ｃｋ相拼接,构建人－鼠嵌合抗体基因。ＳＤＳ－ＰＡＧＥ和Ｗｅｓｔｅｒｎ－Ｂｌｏｔ分析结果证实嵌合抗体重链基因在Ｅ．ｃｏｌｉ中得到了表达。间接ＥＬＩＳＡ法免疫测定的结果表明该表达产物具有与乙肝表面抗原结合的能力。     

抗p185~(erbB2)人鼠嵌合抗体ChAb26转基因小鼠乳腺生物反应器的制备与验证

目的:构建抗p185~(erbB2)人鼠嵌合抗体ChAb26转基因动物乳腺特异性表达载体并制备和验证抗p185~(erbB2)人鼠嵌合抗体ChAb26转基因小鼠乳腺生物反应器模型。方法:利用PCR法扩增出抗人p185~(erbB2)人鼠嵌合抗体ChAb26的重链基因H和轻链基因L,然后分别将嵌合抗体重链基因H和嵌合抗体轻链基因L连接到乳腺特异性表达质粒pBC1,从而构建抗p185~(erbB2)人鼠嵌合抗体ChAb26转基因动物乳腺特异性表达载体pBC1-H和pBC1-L。分别将抗p185~(erbB2)人鼠嵌合抗体ChAb26乳腺特异表达载体pBC1-H和pBC1-L线性化,然后使用原核显微共注射法获得8只转基因FVB小鼠,通过鼠尾直接PCR鉴定其转基因阳性。通过RT-PCR、荧光定量PCR鉴定转基因小鼠乳腺组织中抗p185~(erbB2)人鼠嵌合抗体ChAb26的mRNA表达。使用小鼠乳汁采集器收集其乳汁并通过Western blot和夹心ELISA等实验鉴定抗p185~(erbB2)人鼠嵌合抗体ChAb26是否获得表达。结果:经测序验证,抗p185~(erbB2)人鼠嵌合抗体ChAb26的嵌合重链基因H和嵌合轻链基因L分别与乳腺特异表达质粒pBC1正确正向连接。鼠尾直接PCR结果显示所获8只转基因FVB小鼠均为转基因双阳性小鼠,且抗p185~(erbB2)人鼠嵌合抗体ChAb26的重链基因H和轻链基因L在它们的后代中稳定遗传,它们的后代中转基因小鼠双阳性率约为30%; RT-PCR和荧光定量PCR的结果显示,转基因双阳性小鼠及其双阳性后代的乳腺组织中存在抗p185~(erbB2)人鼠嵌合抗体ChAb26的mRNA表达; Western blot和ELISA等实验结果显示,转基因双阳性小鼠乳汁中存在抗p185~(erbB2)人鼠嵌合抗体ChAb26的蛋白质表达,而且抗p185~(erbB2)人鼠嵌合抗体ChAb26与羊抗人κ链抗体和羊抗人Ig G Fc-HRP抗体均能特异性结合。结论:成功构建抗p185~(erbB2)人鼠嵌合抗体ChAb26转基因动物乳腺特异性表达载体pBC1-H和pBC1-L和制备了抗p185~(erbB2)人鼠嵌合抗体ChAb26转基因小鼠乳腺生物反应器模型,为今后抗p185~(erbB2)人鼠嵌合抗体ChAb26转基因牛乳腺生物反应器的研究奠定了理论和技术基础。     

6C6鼠-人嵌合抗体的纯化及鉴定

采用基因工程技术 ,将小鼠 6C6单克隆抗体可变区基因与人抗体恒定区基因连接 ,构建了鼠 人 6C6嵌合抗体基因 ,并在CHO细胞中高效表达 .利用ProteinA亲和层析柱从细胞培养上清中分离纯化 6C6嵌合抗体 ,得到电泳纯度大于 98%的 6C6嵌合抗体 ,其重链 (5 5kD)和轻链 (2 4kD)符合IgG相对分子质量的理论值 .Western印迹、细胞免疫荧光和免疫组织化学实验结果均呈阳性 .表明6C6嵌合抗体可识别人乳腺癌细胞表面上的肿瘤相关抗原 ,保持了 6C6单克隆抗体的特性 ,为后续的研究工作奠定了基础     

含F／2A序列的抗P185^erbB2人鼠嵌合抗体慢病毒表达载体的构建

目的构建含F／2A序列的抗P185^erbB2人鼠嵌合抗体慢病毒表达载体,观察其在293T细胞中的表达。方法用具有自我剪切能力的弗林蛋白酶（Furin）／口蹄疫病毒2A多肽（F/2A）连接人鼠嵌合抗体的重链和轻链,形成一个开放阅读框（ORF）,插入慢病毒表达载体pWPI,构建重组抗P185神睨全长人鼠嵌合抗体表达载体pWPI／H-F2A—L。以已构建的慢病毒表达载体pWPI／H-IRES-L为对照质粒。应用磷酸钙沉淀法将慢病毒载体3质粒系统共转染入293T细胞进行包装,测定病毒滴度。再感染293T细胞,荧光显微镜下观察GFP的表达和转染效率,RT—PER、ELISA方法分别检测嵌合抗体mRNA和蛋白的表达。结果经测序鉴定,pWPI／H—F2A—L与预期设计一致;pWPI／H—F2A—L组的病毒滴度为4．3×10^5TU／ml,而pWPI／H—IRES—L组的病毒滴度为3．5×10^5TU／ml;两组重组慢病毒的转染效率分别为87．68％和79．08％;两组重组慢病毒感染293T细胞后,都有嵌合重链和嵌合轻链的表达,由F／2A介导的嵌合抗体的表达水平要高于由IRES介导的嵌合抗体。结论成功构建了含F／2A序列的抗P185^erbB2人鼠嵌合抗体慢病毒表达载体,为今后抗P185^erbB2工程抗体的研究奠定了基础。     

抗HEV嵌合抗体的构建及在CHO细胞中的表达

通过RT-PCR方法从分泌戊型肝炎(戊肝)病毒中和性鼠源单克隆抗体(单抗)8C11的杂交瘤细胞中克隆出抗体基因的重链可变区(VH)、轻链可变区(VK)序列,并分别克隆到含有人gamma 1重链和kappa轻链恒定区序列的pcDNA3.1/Hygro和pcDNA3.1( )质粒中,共转染中华仓鼠卵巢癌细胞(CHO)细胞.RT-PCR结果表明,转染的CHO细胞转录了嵌合重链及轻链基因,间接ELISA及Western blot结果表明:翻译出的两种多肽在细胞内正确组装成嵌合抗体分子,并可分泌至细胞外,表达的嵌合抗体保留了原鼠单抗的抗原结合特异性及对8H3结合抗原的增强作用.8C11嵌合抗体的成功表达可降低鼠源性,为探讨戊肝抗体治疗的可能性奠定了基础.     

功能性抗HBsAg人—鼠嵌合抗体在昆虫细胞中的高效表达

经同源重组我们构建了同时含抗乙肝病毒表面抗原嵌合抗体重、轻链基因的双重组 ＢａｃＨＬ４．２。利用双重感染和双重组病毒感染秋粘虫Ｓｆ９细胞,ＳＤＳ－ＰＡＧＥ结果说明嵌合抗体重、轻链同时在胞内得到了表达。Ｗｅｓｔｅｒｎ ｂｌｏｔ分析表明两种情况均能在胞内组装成Ｈ２Ｌ２完整免疫球蛋白分子。ＥＬＩＳＡ和功能性免疫迷检测证明重组嵌合抗体与父本鼠源单抗ＯＨ３一样能特异性识别具有天然构象的ＨＢｓＡｇ,而不识别经     

抗H5N1病毒嵌合IgA抗体基因的构建及其在CHO细胞中的表达

为了表达具有中和活性的抗禽流感H5N1病毒人-鼠嵌合IgA抗体,采用RT-PCR法克隆具有中和活性的抗禽流感H5N1-HA鼠源单克隆抗体的轻重链可变区基因及相应的信号肽编码序列,分别与人免疫球蛋白IgA2重链恒定区、Kappa恒定区基因拼接,构建表达质粒pEF-IGHA9和pEF-IGK9,共转染二氢叶酸还原酶缺陷型CHO(CHO-dhfr-)细胞,用ELISA检测培养上清中嵌合IgA抗体的表达,对纯化的嵌合抗体进行SDS-PAGE、Western blotting印迹分析。结果成功地在CHO细胞中表达了抗禽流感H5N1病毒人-鼠嵌合IgA抗体,为制备抗H5N1重组分泌型IgA预防性抗体制剂奠定了良好的基础。     

抗品胚抗原单链抗休基因在家蚕细胞和幼虫中的表达

将抗癌胚抗原（ＣＥＡ）单链抗体基因插入家蚕杆状病毒转移载体ｐＢａｃＰＡＫ－Ｈｉｓ,与修饰的家蚕核型多角体病毒Ｂｍ－ＢａｃＰＡＫ ＤＮＡ共转染家蚕细胞,经同源重组得到含有在多角体蛋白基因启动子控制下的抗ＣＥＡ ＳｃＦｖ基因的重组病毒Ｂｍ－ＢａｃＳｃＦｖ。用重组病毒分别感染家蚕细胞和幼虫,在两者中均得到了高效表达,产物分子量为２８ｋＤ,前者占细胞总蛋白的６％,后者为０．３ｍｇ／蚕。目的基因在家蚕细胞和     

Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody specific for pre-S2 antigen of hepatitis B virus.

Binding specificity of a monoclonal antibody (mAb) (kappa, gamma 2b) H8 which can react with the pre-S2 peptide of hepatitis B virus (HBV) was determined by Western blot analyses. From the hybridoma cell line secreting mAb H8, poly(A)+ RNA was prepared and used as a template for cDNA synthesis and cloning. Full-length cDNAs coding for the heavy and kappa light chains of the mAb were cloned from the cDNA library and characterized by nucleotide (nt) sequence analyses and N-terminal amino acid sequencing. The sequence analyses revealed that both heavy and light chain-specific cDNAs are functional, and the variable regions of the heavy and light chains are members of mouse heavy chain subgroup III(c) and light chain group I, respectively. Comparison of the nt sequences with mouse immunoglobulin genes listed in the GenBank data base show that the cDNAs have not been previously reported. The cDNAs will be used for the construction of a therapeutic antibody for HBV infection.     

Expression in COS cells of a mouse-human chimaeric B72.3 antibody

B72.3 is a mouse hybridoma cell-line secreting an IgG1 antibody which recognises an epitope on a tumour-associated antigen, TAG-72. This high molecular weight mucin-like molecule is found on a variety of human neoplasms, including colon, breast and ovarian carcinomas. Chimaeric immunoglobulin genes with the B72.3 specificity have been constructed by joining the mouse variable regions from cDNA clones to human genomic constant regions using recombinant DNA techniques. The chimaeric heavy and light chain immunoglobulin genes were placed under the control of a strong viral promoter, and co-transfected into COS-1 cells. SDS-PAGE analysis of the 35S-labelled products demonstrated that the transiently expressed antibodies were correctly synthesised and assembled. The specific binding characteristics of the parent B72.3 antibody were retained by the chimaeric antibody in an antigen-based ELISA. This system gave sufficiently high transient expression of the chimaeric antibody molecules to allow rapid physical and immunological characterisation of the engineered gene products.     

Domain characterization of rabbit skeletal muscle myosin light chain kinase.

Myosin light chain kinase can be divided into three distinct structural domains, an amino-terminal "tail," of unknown function, a central catalytic core and a carboxy-terminal calmodulin-binding regulatory region. We have used a combination of deletion mutagenesis and monoclonal antibody epitope mapping to define these domains more closely. A 2.95-kilobase cDNA has been isolated that includes the entire coding sequence of rabbit skeletal muscle myosin light chain kinase (607 amino acids). This cDNA, expressed in COS cells encoded a Ca2+/calmodulin-dependent myosin light chain kinase with a specific activity similar to that of the enzyme purified from rabbit skeletal muscle. Serial carboxy-terminal deletions of the regulatory and catalytic domains were constructed and expressed in COS cells. The truncated kinases had no detectable myosin light chain kinase activity. Monoclonal antibodies which inhibit the activity of the enzyme competitively with respect to myosin light chain were found to bind between residues 235-319 and 165-173, amino-terminal of the previously defined catalytic core. Thus, residues that are either involved in substrate binding or in close proximity to a light chain binding site may be located more amino-terminal than the previously defined catalytic core.     

Evaluation of immunoglobulins from plant cells.

Expression of cDNA constructs encoding full-length mouse immunoglobulin chains with their native leader sequences or fusion constructs substituting the native leader with a pre-pro sequence derived from Saccharomyces cerevisiae yielded blocked N-termini on the gamma chain or the correct amino terminal sequence on the mature kappa chain. Lectin binding assays revealed that assembled immunoglobulin complexes contained a glycosylated heavy chain. The attached glycan was resistant to digestion by endoglycosidase H and its lectin binding pattern was distinguishable from that of the mammalian glycan. The results indicated processing of the immunoglobulin carbohydrate in the tobacco Golgi to yield a complex oligosaccharide. Secretion of antibody by protoplasts isolated from regenerated transgenic plants or from suspension callus cells was demonstrated by pulse-chase labeling experiments. When purified, the tobacco-produced antibody was found to possess the antigen binding and catalytic properties of the murine monoclonal antibody. Kinetic parameters (Km, Ki, Vmax, and kcat) of the tobacco-derived antibody were comparable to those of the mouse-derived antibody. The results in general show that the endomembrane system of tobacco cells possesses cognate mechanisms for the recognition of diverse leader sequences. These signals can be used to initiate the assembly, processing, and secretion by plant cells of complex foreign proteins.     

Expression in non-lymphoid cells of mouse recombinant immunoglobulin directed against the tumour marker human placental alkaline phosphatase

From a mouse hybridoma cell line secreting a monoclonal antibody directed against the tumour marker human placental alkaline phosphatase, mRNA coding for the H and L chains of this antibody was isolated and cloned as cDNA. Sequence analysis of the H and L chain cDNAs confirmed the IgG2b,kappa subtype previously established. Recloning the H and L chain cDNA information into SV40-based vectors enabled us to obtain expression of functional immunoglobulin upon cotransfection into COS or CHO dhfr- cells. This illustrates that non-lymphoid cells also have the capacity to assemble active immunoglobulins.     

Vectors for the expression of PCR-amplified immunoglobulin variable domains with human constant regions.

Cassette vectors have been constructed for mammalian expression of complete immunoglobulin heavy and light chain genes whose variable regions are produced by the polymerase chain reaction (PCR). The light and heavy chain vectors have promoter, leader, partial intron, enhancer and constant region segments within modified pSV2-gpt and pSV2-neo plasmids, respectively. Variable (V) regions are obtained by PCR using a two step process: 1) the V gene is amplified from genomic or cDNA, cloned into an intermediate vector and sequenced; 2) the first PCR product serves as the template for a second amplification in which restriction enzyme recognition sites and limited flanking intron sequence are added. The second PCR product is inserted into the expression vector, which is then transfected into mouse myeloma cells. These vectors contain human constant regions and may be used to express chimeric, humanized or human Ig genes. This report describes the design of these vectors and their application for the expression of chimeric 60.3, an anti-CD18 antibody.     

转植酸酶基因家蚕的制作及表达检测

家蚕Bombyx mori丝腺具有高效合成蛋白质的特性,开发在丝腺特异表达外源蛋白质的生物反应器具有重要的意义。本研究利用piggyBac来源的两种载体pPIGA3GFP和pBac{3×P3-EGFPaf},建立了稳定的家蚕转基因技术体系; 然后,利用一株黑曲霉来源的植酸酶基因,构建了在家蚕后部丝腺特异表达的融合表达载体pBac [3×P3-EGFP+ FibLphyADsRed],注射蚕卵后,在53个G1蛾区中检测到3个有荧光蚕的蛾区。经Southern blot和反向PCR验证,转基因表达盒整合到家蚕染色体上。RT-PCR结果显示,植酸酶基因特异性地在后部丝腺表达,其表达模式与家蚕轻链丝素基因一致。结果表明我们成功获得了在后部丝腺特异表达植酸酶融合蛋白的转基因蚕,这为进一步开发家蚕生物反应器,利用转基因蚕生产各种重组蛋白具有积极的促进作用。